We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 24, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ExxonMobil Corp. (XOM - Free Report) , The Coca-Cola Co. (KO - Free Report) , AstraZeneca PLC (AZN - Free Report) , CSX Corp. (CSX - Free Report) and Activision Blizzard, Inc. .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for ExxonMobil, Coca-Cola and AstraZeneca
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil Corp., The Coca-Cola Co. and AstraZeneca PLC. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of ExxonMobil have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+44.8% vs. +24.1%). This reflects the company’s bellwether status and an optimal integrated capital structure that has historically produced industry-leading returns make it a relatively lower-risk energy sector play. The company has made more than 30 discoveries in offshore Guyana since 2015.
ExxonMobil also has a strong presence in the prolific Permian Basin, where it delivered record production in the third quarter. Considering the low cost of production in both assets, ExxonMobil will continue to generate handsome returns. Also, a strong presence in chemicals and refining operations is noteworthy.
However, ExxonMobil has constantly been bearing the brunt of increasing expenses, adversely affecting its income. Also, the integrated energy giant’s financials were weakened by years-long significant spending on low-return developments and the coronavirus pandemic.
Shares of Coca-Cola have underperformed the Zacks Beverages - Soft drinks industry over the past year (-0.9% vs. +7.0%). The company is facing pressures from higher transportation and input costs. Higher marketing spends and currency headwinds are concerning.
Nevertheless, Coca-Cola’s sales and earnings surpassed estimates for the seventh straight quarter. KO’s results benefited from the continued momentum from the first half of 2022. Sales gained from revenue growth across its operating segments, aided by an improved price/mix and an increase in concentrate sales.
Coca-Cola gained from underlying share gains in both at-home and away-from-home channels. We estimate organic revenue growth of 14.8% and comparable earnings per share growth of 6.6%, in line with the company’s raised view for 2022. Innovations and accelerating digital investments bode well.
AstraZeneca shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+18.4% vs. +13.6%). The company’s key drugs, mainly cancer medicines, Lynparza, Tagrisso and Imfinzi should keep driving revenues. Its pipeline is strong with several phase III data readouts lined up.
AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets. The Alexion buyout strengthens its immunology franchise, adding several drugs that are boosting its top line.
However, AstraZeneca’s diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit. Sales are slowing down in its key market, China. Shares have outperformed the industry in the past one year. Estimate movement is mixed ahead of the Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters.
Other noteworthy reports we are featuring today include CSX Corp. and Activision Blizzard, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights ExxonMobil, Coca-Cola, AstraZeneca, CSX and Activision Blizzard
For Immediate Release
Chicago, IL – February 24, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: ExxonMobil Corp. (XOM - Free Report) , The Coca-Cola Co. (KO - Free Report) , AstraZeneca PLC (AZN - Free Report) , CSX Corp. (CSX - Free Report) and Activision Blizzard, Inc. .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for ExxonMobil, Coca-Cola and AstraZeneca
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil Corp., The Coca-Cola Co. and AstraZeneca PLC. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of ExxonMobil have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+44.8% vs. +24.1%). This reflects the company’s bellwether status and an optimal integrated capital structure that has historically produced industry-leading returns make it a relatively lower-risk energy sector play. The company has made more than 30 discoveries in offshore Guyana since 2015.
ExxonMobil also has a strong presence in the prolific Permian Basin, where it delivered record production in the third quarter. Considering the low cost of production in both assets, ExxonMobil will continue to generate handsome returns. Also, a strong presence in chemicals and refining operations is noteworthy.
However, ExxonMobil has constantly been bearing the brunt of increasing expenses, adversely affecting its income. Also, the integrated energy giant’s financials were weakened by years-long significant spending on low-return developments and the coronavirus pandemic.
(You can read the full research report on Exxom Mobil here >>>)
Shares of Coca-Cola have underperformed the Zacks Beverages - Soft drinks industry over the past year (-0.9% vs. +7.0%). The company is facing pressures from higher transportation and input costs. Higher marketing spends and currency headwinds are concerning.
Nevertheless, Coca-Cola’s sales and earnings surpassed estimates for the seventh straight quarter. KO’s results benefited from the continued momentum from the first half of 2022. Sales gained from revenue growth across its operating segments, aided by an improved price/mix and an increase in concentrate sales.
Coca-Cola gained from underlying share gains in both at-home and away-from-home channels. We estimate organic revenue growth of 14.8% and comparable earnings per share growth of 6.6%, in line with the company’s raised view for 2022. Innovations and accelerating digital investments bode well.
(You can read the full research report on Coca-Cola here >>>)
AstraZeneca shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+18.4% vs. +13.6%). The company’s key drugs, mainly cancer medicines, Lynparza, Tagrisso and Imfinzi should keep driving revenues. Its pipeline is strong with several phase III data readouts lined up.
AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets. The Alexion buyout strengthens its immunology franchise, adding several drugs that are boosting its top line.
However, AstraZeneca’s diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit. Sales are slowing down in its key market, China. Shares have outperformed the industry in the past one year. Estimate movement is mixed ahead of the Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters.
(You can read the full research report on AstraZeneca here >>>)
Other noteworthy reports we are featuring today include CSX Corp. and Activision Blizzard, Inc.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.